Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pimecrolimus
Drug ID BADD_D01773
Description Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Indications and Usage For treatment of mild to moderate atopic dermatitis.
Marketing Status approved; investigational
ATC Code D11AH02
DrugBank ID DB00337
KEGG ID D05480
MeSH ID C117268
PubChem ID 6447131
TTD Drug ID D0Z4UN
NDC Product Code 55486-1585; 68682-112; 62227-004; 68254-0014; 0187-5102; 0591-2944; 62227-024; 65727-045; 0187-5101; 53296-0115; 0187-5100; 68682-110; 68462-609; 68682-111; 51552-1620; 16436-0115; 0187-5103
UNII 7KYV510875
Synonyms pimecrolimus | 33-epi-chloro-33-desoxyascomycin | SDZ ASM 981 | SDZ-ASM-981 | ASM 981 | Elidel
Chemical Information
Molecular Formula C43H68ClNO11
CAS Registry Number 137071-32-0
SMILES CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C 4)OC)Cl)C)O)C)OC)OC)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pharyngitis streptococcal22.07.04.001; 11.02.06.002--Not Available
Photosensitivity reaction23.03.09.003--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pruritus23.03.12.0010.002053%
Pyrexia08.05.02.003--
Rash23.03.13.0010.001260%Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.12.03.021--
Sinus congestion22.04.06.001--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin atrophy23.01.05.001--
Skin cancer23.08.02.002; 16.03.02.002--Not Available
Skin discolouration23.03.03.0050.001586%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.000466%Not Available
Skin hyperpigmentation23.05.01.003--
Skin infection23.11.04.007; 11.01.12.003--
Skin irritation23.03.04.0090.001586%Not Available
Skin papilloma23.10.01.002; 16.26.01.002; 11.05.07.001--
Squamous cell carcinoma16.16.01.002--Not Available
Steroid withdrawal syndrome08.06.02.013; 05.01.02.007; 19.04.02.0140.000466%Not Available
Superinfection11.01.08.009--Not Available
Swelling08.01.03.0150.000700%Not Available
Tonsillitis22.07.03.008; 11.01.13.006--Not Available
Toothache07.09.06.001--
Tracheobronchitis22.07.01.016; 11.01.09.020--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.0010.001026%
Varicella23.11.05.008; 11.05.02.004--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages